A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Dose Escalation of GS1-144 Tablets and the Effects of Food on the Pharmacokinetics of GS1-144 in a Chinese Population
Latest Information Update: 16 May 2025
At a glance
- Drugs GS1 144 (Primary)
- Indications Vasomotor symptoms
- Focus Adverse reactions
- Sponsors GeneScience Pharmaceuticals
Most Recent Events
- 08 May 2025 Status changed from recruiting to completed.
- 30 Apr 2024 New trial record